SERB–Hansa Idefirix Deal | Lucid Diligence Brief
SERB’s Idefirix rights acquisition from Hansa Biopharma sharpens its rare…
Bionyra Pharma Launches With $165M to Advance Immunology Biologics | Lucid Diligence Brief
Bionyra Pharma launched with $165M to advance TL1A, IL-23 and IL-25 biologics…
AbbVie's Apogee Acquisition Valued at $10.9B. | Lucid Diligence Brief
AbbVie’s Apogee deal adds zumilokibart and asthma assets as immunology growth…
Vedana Therapeutics Advances Migraine Antibody Pipeline | Lucid Diligence Brief
Vedana Therapeutics has emerged from stealth with $46 million in Series A…
Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…
Lucid Diligence Brief: NeuroXT and BIDMC Expand Alzheimer’s AI Imaging Collaboration
Lucid Diligence Brief: NeuroXT and BIDMC expand their Alzheimer’s AI imaging…
Lucid Diligence Brief: Genethon and Ampersand Biomedicines AAV Partnership
Lucid Diligence Brief: Genethon and Ampersand Biomedicines partner to design…
Lucid Diligence Brief: BMS Deploys Anthropic Claude Enterprise
Lucid Diligence Brief: BMS Deploys Anthropic Claude Enterprise Across R&D,…
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License
Lucid Diligence Brief: ERS Genomics’ CRISPR/Cas9 IP license to Aurigene raises…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…